CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...
Phase 3
Birmingham, Alabama, United States and 125 other locations
to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic s...
Phase 1, Phase 2
Birmingham, Alabama, United States and 33 other locations
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed th...
Phase 1
Birmingham, Alabama, United States and 32 other locations
This trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of AML carrying a particular geneti...
Phase 1, Phase 2
Birmingham, Alabama, United States and 3 other locations
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (A...
Phase 1, Phase 2
Birmingham, Alabama, United States and 13 other locations
and pharmacokinetics, of CB-012 (the study treatment) in adults with acute myeloid leukemia (AML) that has come b...
Phase 1
Birmingham, Alabama, United States and 9 other locations
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Phase 3
Birmingham, Alabama, United States and 102 other locations
with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome ...
Phase 1
Birmingham, Alabama, United States and 14 other locations
available therapy (BAT) on overall survival (OS) in subjects with acute myeloid leukemia (AML) who are in second ...
Phase 3
Birmingham, Alabama, United States and 72 other locations
it is safe for participants with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It will study S...
Phase 1
Birmingham, Alabama, United States and 49 other locations
Clinical trials
Research sites
Resources
Legal